Heart failure in children: Management

Authors: Rakesh K Singh, MD, MS, TP Singh, MD, MSc

Section Editor: John K Triedman, MD
Deputy Editor: Carrie Armsby, MD, MPH

Contributor Disclosures

All topics are updated as new evidence becomes available and our peer review process is complete.

Literature review current through: Jan 2024. | This topic last updated: Nov 29, 2022.

INTRODUCTION

Heart failure (HF) results from structural or functional cardiac disorders that impair
the ability of the ventricle(s) to fill with and/or eject blood. The presentation of
pediatric HF is diverse because of the numerous underlying cardiac etiologies
( table 1) and varying clinical settings.

The management of HF in children will be presented here. The etiology, clinical

manifestations, and diagnostic evaluation of HF in children are discussed separately.
(See "Heart failure in children: Etiology, clinical manifestations, and diagnosis".)

GENERAL MEASURES

General measures that can be applied to all pediatric patients with HF include
correcting reversible conditions that may be causing or contributing the HF
symptoms, ensuring adequate nutrition, and promoting healthy and safe exercise.

Reversible contributors — Patients with HF may have comorbidities that can

exacerbate or contribute to cardiac dysfunction. A thorough evaluation should be
performed in all patients to identify such contributors and appropriate therapy should
be provided if warranted. Examples include:
● Iron deficiency and anemia – Iron deficiency, with or without anemia, is common
in patients with HF and is associated with worse symptoms and clinical outcomes
[1-5]. Iron studies and appropriate therapy should be considered in all children
with HF even in absence of anemia. Patients with HF and comorbid iron deficiency
 may not respond adequately to oral iron supplementation [6]. Thus, some
patients may require intravenous iron therapy. (See "Iron deficiency in infants and
children <12 years: Treatment" and "Evaluation and management of anemia and
iron deficiency in adults with heart failure", section on 'Iron supplementation'.)
● Hypertension. (See "Nonemergent treatment of hypertension in children and
adolescents".)
● Renal failure. (See "Chronic kidney disease in children: Overview of
management".)
● Acidosis. (See "Approach to the child with metabolic acidosis".).
● Obesity. (See "Prevention and management of childhood obesity in the primary
care setting".)
● Malnutrition. (See 'Nutritional support' below and "Poor weight gain in children
younger than two years in resource-abundant settings: Management" and "Poor
weight gain in children older than two years in resource-abundant settings".)
● Respiratory disorders (eg, asthma, obstructive sleep apnea, interstitial lung
disease). (See "An overview of asthma management" and "Management of
obstructive sleep apnea in children" and "Approach to the infant and child with
diffuse lung disease (interstitial lung disease)".)
● Thyroid disorders (hypo- or hyperthyroid state) or adrenal insufficiency. (See
"Acquired hypothyroidism in childhood and adolescence" and "Clinical
manifestations and diagnosis of Graves disease in children and adolescents" and
"Clinical manifestations and diagnosis of adrenal insufficiency in children".)

Nutritional support — Caloric intake and growth should be carefully assessed in

infants and children with HF. Children with HF often have increased caloric needs due
to an increased metabolic demand. In addition, patients with HF often tire with
feeding and their intake may be limited. Some children may need a daily intake >120
kcal/kg for optimal growth. In order to provide adequate caloric intake, intermittent
or continuous nasogastric or gastrostomy tube feeds may be required. In addition,
salt and fluid restriction is recommended in children with severe HF to reduce volume
overload. (See "Overview of enteral nutrition in infants and children".)
Growth failure and poor weight gain are common in infants and children with HF and
are associated with poor outcome [7,8]. Approximately one-quarter of children with
cardiomyopathy manifest growth failure during the course of their illness [8,9]. In a
registry study that analyzed data from >900 children with dilated cardiomyopathy,
children with poor weight gain (defined as body mass index or weight-for-height <5th
percentile for age) had an increased risk of death compared with children of normal
weight (hazard ratio 2.1; 95% CI 1.7-3.6) [8].

Exercise and physical activity — Promoting healthy and safe physical activity in
patients with HF is an important part of management. The challenge is to balance
routine daily physical activity while minimizing any potential risks from exercise.
Recommendations should be tailored for each individual based on his or her specific
diagnosis and a comprehensive assessment of the child's exercise capacity. This
should generally include formal cardiopulmonary exercise testing if feasible (ie, if the
child is old enough to cooperate, typically beginning around age 6 or 7 years). (See
"Exercise testing in children and adolescents: Principles and clinical application",
section on 'Limitations in young children'.)

Physical activity and exercise in patients with congenital heart disease (CHD) are
discussed in greater detail separately. (See "Physical activity and exercise in patients
with congenital heart disease".)

In adults with chronic HF, cardiovascular rehabilitation programs have been shown to
improve exercise performance, physical activity, and quality of life [10]; however, data
in children are limited. In a single-center study, 15 of 16 children with complex CHD
demonstrated improved exercise performance after participation in a cardiac
rehabilitation program [11]. Furthermore, a study of 20 hospitalized children awaiting
heart transplantation demonstrated that even those on inotropic support can safely
participate in exercise training programs with relatively moderate to high compliance
[12]. Further studies are needed to evaluate the long-term benefits of exercise
rehabilitation in children with HF.

APPROACH TO HF MANAGEMENT
The management of pediatric HF is dependent on its etiology and severity [13-15].
Management begins with a thorough assessment of the underlying cause of HF. The
causes of pediatric HF can be divided into pathophysiologic categories ( table 1).
This categorization helps guide the approach to management. (See "Heart failure in
children: Etiology, clinical manifestations, and diagnosis", section on 'Etiology and
pathophysiology'.)

Our management approach is generally consistent with the 2014 International Society
of Heart and Lung Transplantation (ISHLT) guidelines for the treatment of HF in
children, which are primarily based on the adult literature [13]. Modifications for
specific pediatric diagnoses were recommended based on expert consensus that was
largely informed by clinical experience, small case series, and physiologic studies.

Goals of therapy — Therapeutic goals for children with HF are to relieve symptoms,
decrease morbidity (including the risk of hospitalization), slow the progression of HF,
and improve patient survival and quality of life.

Unstable patients — In patients who present with severe cardiorespiratory

compromise (ie, shock or impending cardiac arrest), prompt initiation of treatment to
restore adequate perfusion should be provided even if the underlying etiology is
uncertain. Guidance for management of shock is summarized in the figures and
discussed in detail separately:
● For neonates ( algorithm 1) (see "Neonatal shock: Management")
● For older infants and children ( algorithm 2) (see "Shock in children in resource-
abundant settings: Initial management")

Structural heart disease with preserved ventricular function — For patients with
preserved ventricular function who have HF symptoms due to structural heart defects
causing volume overload (eg, septal defects, patent ductus arteriosus) or pressure
overload (eg, pulmonic stenosis, aortic stenosis, other right or left ventricular outflow
tract obstruction) ( table 1), the mainstay of management involves surgical or
catheter-based interventions to correct the underlying defects. Medical therapy may
be needed for stabilization or symptom relief while awaiting a more definitive
intervention. (See 'Pharmacologic therapy' below.)
The appropriate intervention depends upon the specific defect. Common examples
include:
● Atrial septal defects – Management involves surgical or percutaneous closure of
the defect. (See "Isolated atrial septal defects (ASDs) in children: Management
and outcome", section on 'Closure procedures'.)
● Ventricular septal defects – Surgical closure is generally preferred. (See
"Management of isolated ventricular septal defects (VSDs) in infants and
children", section on 'Closure interventions'.)
● Patent ductus arteriosus – Surgical ligation is used in young infants;
percutaneous occlusion is more commonly used in older infants and children.
(See "Management of patent ductus arteriosus (PDA) in term infants, children,
and adults", section on 'Management approach'.)
● Valvular aortic stenosis – Percutaneous balloon aortic valvotomy is the therapy of
choice. (See "Subvalvar aortic stenosis (subaortic stenosis)".)
● Pulmonic stenosis – Percutaneous balloon valvotomy is usually performed. (See
"Pulmonic stenosis in infants and children: Management and outcome".)

Interventions for other congenital heart defects are discussed in separate topic
reviews.

Impaired ventricular function — For patients with ventricular systolic dysfunction or

those who require stabilization before surgical or catheter-based correction, therapy
is provided based on the stage of HF ( table 2):
● Stage A – For patients at risk for HF who have normal cardiac function and size,
we recommend not treating with HF-specific therapies. Predisposing conditions
should be treated if possible, as previously discussed. (See 'Reversible
contributors' above.)
● Stage B – For asymptomatic patients with abnormal systemic ventricular
function, pharmacologic therapy consists of angiotensin-converting enzyme (ACE)
inhibitors. Angiotensin II receptor blockers (ARBs) can be used in patients who
are intolerant of ACE inhibitors. (See 'Renin-angiotensin-aldosterone system
inhibition' below.)
 Based on adult guidelines, beta blockers can be considered in children with
asymptomatic systolic LV dysfunction. It is important to note, however, that adult
studies to support this recommendation are limited to patients with ischemic
heart disease. (See 'Beta blockers' below.)
● Stage C – For patients with current or past symptoms and structural or functional
heart disease, we suggest initial treatment with an ACE inhibitor plus a
mineralocorticoid receptor antagonist. Oral diuretic therapy should be provided
as needed for fluid overload. After a few weeks of stability, a beta blocker is
usually added in patients with persistent left ventricle dilation and dysfunction.
Low-dose digoxin can be added if needed for additional symptom relief. (See
'Pharmacologic therapy' below.)

For patients with stage C HF that is associated with severe limitation of activity,
significant growth failure, intractable arrhythmias, or restrictive cardiomyopathy,
early referral to a pediatric transplant center should be considered to optimize
medical therapy and the timing of listing for heart transplant. (See 'Heart
transplantation' below.)
● Stage D – Interventions for patients with end-stage HF who are refractory to oral
medical therapy may include intravenous administration of inotropes and
diuretics and nonpharmacologic interventions such as positive pressure
ventilation, cardiac resynchronization therapy (CRT), mechanical circulatory
support, and heart transplantation. Some patients present in stage D
(decompensated state) and after initial acute therapy with inotropes may be able
to transition to oral HF therapy as described above for patients in stage C. (See
'Drug therapy for advanced HF' below and 'Nonpharmacologic interventions for
advanced HF' below.)

PHARMACOLOGIC THERAPY

Pharmacologic therapy is primarily used in patients with ventricular pump

dysfunction. Drug therapy is also used initially to stabilize and relieve symptoms in
patients with either volume or pressure overload with preserved ventricular function
who are awaiting correction of the underlying defect.
Evidence for efficacy — For most of the agents used in the management of children
with HF, the evidence supporting efficacy comes largely from adult studies. Because
HF is common in adults, there is a substantial amount of clinical trial data to guide
management decisions. Treatment strategies are based on observations that left
ventricular (LV) systolic dysfunction activates sympathetic nervous and renin-
angiotensin systems. This response is initially physiologic (and compensatory), but
persistent activation is maladaptive and contributes to progressive LV dilation and
dysfunction (remodeling), and worsening HF. Data from clinical trials have shown that
drugs targeted to block the effects of neuro-hormonal activation (eg, beta blockers,
angiotensin-converting enzyme [ACE] inhibitors) not only reverse LV remodeling but
also improve survival in patients with HF. (See "Overview of the management of heart
failure with reduced ejection fraction in adults" and "Primary pharmacologic therapy
for heart failure with reduced ejection fraction", section on 'Management of specific
agents'.)

However, the prevalence of HF in the pediatric population is substantially lower than

in adults which limits the ability to conduct similar trials in children. As a result,
treatment of HF in children is based in large part on indirect evidence from adult
studies. This approach is supported by observations that children with HF have neuro-
hormonal changes and systemic ventricular remodeling similar to that described in
adults with HF [16-19].

Specific agents

Diuretics — Diuretics decrease preload by promoting natriuresis, and provide relief

of volume overload symptoms such as pulmonary and peripheral edema. Diuretics
are used to treat children with stage C or D HF ( table 2):
● Loop diuretics – Loop diuretics inhibit sodium and chloride reabsorption in the
thick ascending limb of the loop of Henle. Furosemide is the most commonly
used loop diuretic. A study of 62 hospitalized children with HF and fluid overload
demonstrated the efficacy and safety of furosemide [20]. Bumetanide and
torsemide are more potent drugs, which are used less frequently and reserved
for more severe or furosemide-resistant fluid overload. Side effects of loop
diuretics include electrolyte abnormalities (hyponatremia, hypochloremia, and
 hypokalemia), metabolic alkalosis, and renal insufficiency. Long-term therapy can
lead to nephrocalcinosis and ototoxicity. These complications occur most
commonly with prolonged high-dose intravenous (IV) therapy [21]. Increased risk
of bone fractures has also been reported [22].
● Thiazide diuretics – Thiazide diuretics inhibit reabsorption of sodium and
chloride ions from the distal convoluted tubules of kidneys. They generally are
used as second-line agents and often in combination with a loop diuretic.
Commonly used thiazide diuretics are chlorothiazide, hydrochlorothiazide, and
metolazone.

Renin-angiotensin-aldosterone system inhibition — HF leads to activation of the

renin-angiotensin-aldosterone system (RAAS) and increased sympathetic tone. Agents
that block RAAS activation include ACE inhibitors, angiotensin II receptor blockers
(ARBs), and angiotensin receptor-neprilysin inhibitors (ARNIs). These agents decrease
afterload and promote reversal of ventricular remodeling.

ACE inhibitors — ACE inhibitors are an accepted first-line component of therapy

for children with stage B and C HF ( table 2).

ACE inhibitors are generally well tolerated in children and adverse effects are
uncommon [23]. Blood pressure and renal function should be monitored when
initiating therapy, especially in neonates [24].

Clinical trials in adults have shown that ACE inhibitors improve survival in patients
with symptomatic HF and reduce the rate at which asymptomatic patients with severe
LV dysfunction develop symptomatic HF. (See "Primary pharmacologic therapy for
heart failure with reduced ejection fraction", section on 'Sacubitril-valsartan, ACE
inhibitor, or ARB'.)

Clinical trial data on the use of ACE inhibitors in children are limited and have been
difficult to interpret due to healthier baseline cohorts, smaller sample size, and
shorter duration of follow-up compared with adult studies.

In a randomized, placebo-controlled, crossover trial of enalapril in 18 subjects (mean

age 14 years old) who were 4 to 19 years post-Fontan operation, the use of enalapril
for 10 weeks was not associated with change in cardiac function or exercise
performance [25]. In a subsequent randomized, placebo-controlled study of enalapril
in 230 infants with single ventricle anatomy and predominantly normal systemic
ventricular function, somatic growth, ventricular function, HF severity, and one-year
mortality were similar in the enalapril and placebo groups [26]. In another
randomized placebo-controlled trial of perindopril in 57 children with Duchenne
muscular dystrophy (DMD) with normal LV ejection fraction (LVEF), LV function was
similar in both groups at the trial's end (three years) [27]. However, fewer patients in
the perindopril group had LVEF <45 percent at five years (4 versus 28 percent) and
fewer deaths were observed in the perindopril group at 10 years (7 versus 34 percent)
[27,28]. The small size of the study limits drawing a firm conclusion regarding a
possible mortality benefit.

Small nonrandomized trials and observational studies in other types of pediatric HF

patients have demonstrated physiologic benefits and improvements in short-term
outcomes [29-31]. Other studies have found no benefit or only limited efficacy [32,33].

Despite the inconsistencies and limitations of the pediatric data, it is reasonable to

believe that the well-established benefits of ACE inhibitors in adult HF patients likely
apply to pediatric patients as well.

ACE inhibitors inhibit the formation of angiotensin II, a potent vasoconstrictor that
also promotes myocyte hypertrophy, fibrosis, and aldosterone secretion [13]. Thus,
ACE inhibitors benefit patients in HF first by reducing afterload, improving cardiac
output, and, on chronic use, by mediating reversal of LV remodeling. (See
"Pharmacologic therapy of heart failure with reduced ejection fraction: Mechanisms of
action", section on 'ACE inhibitors'.)

Angiotensin II receptor blockers (ARBs) — In children with HF, there is a

paucity of data on the use of ARBs, which block the angiotensin receptor (eg,
candesartan, losartan, valsartan). Thus, ACE inhibitors are the preferred class of drugs
for inhibition of the RAAS. ARBs are usually reserved for patients unable to tolerate
ACE inhibitors due to cough or angioedema. (See "Pharmacologic therapy of heart
failure with reduced ejection fraction: Mechanisms of action", section on 'Angiotensin
II receptor blockers' and "Primary pharmacologic therapy for heart failure with
reduced ejection fraction", section on 'Sacubitril-valsartan, ACE inhibitor, or ARB'.)
 Angiotensin receptor-neprilysin inhibitor (ARNI) — The combination drug
sacubitril-valsartan (a neprilysin inhibitor plus an ARB) is the only agent in this class.
Sacubitril-valsartan has been shown to reduce mortality when compared with
enalapril in adults with HF. The PANORAMA-HF trial was designed to evaluate the
efficacy and safety of sacubitril-valsartan in pediatric patients with HF due to systolic
dysfunction (LVEF ≤40 percent) [34,35]. The trial enrolled 360 patients who were
randomly assigned to sacubitril-valsartan or enalapril. Patients are being followed for
52 weeks and the full results of the trial are not yet available. Based on preliminary
results from the PANORAMA-HF trial, the US Food and Drug Administration (FDA)
approved sacubitril-valsartan for use in children ≥1 year old in 2019 [36]. The FDA's
approval of this drug for pediatric use was based upon an unpublished analysis of 110
pediatric patients enrolled in the PANORAMA-HF trial, the results of which are
available only on the FDA label [36]. At 12 weeks, patients treated with sacubitril-
valsartan had greater reduction in plasma N-terminal pro-B-type natriuretic peptide
(NT-proBNP) levels compared with those receiving enalapril (44 versus 33 percent,
respectively); however, the difference was not statistically significant. According to the
FDA label, adverse reactions observed in pediatric patients treated with sacubitril-
valsartan were similar to those observed in adult patients (hypotension and
hyperkalemia, being the most common). Additional data from the complete trial will
be important to fully assess the safety and efficacy of this agent in pediatric patients.
(See "Pharmacologic therapy of heart failure with reduced ejection fraction:
Mechanisms of action", section on 'Angiotensin receptor-neprilysin inhibitor (ARNI)'
and "Primary pharmacologic therapy for heart failure with reduced ejection fraction",
section on 'Sacubitril-valsartan, ACE inhibitor, or ARB'.)

Mineralocorticoid receptor antagonists — MRAs (eg, spironolactone, eplerenone)

decrease sodium reabsorption and potassium excretion in the collecting ducts of
kidneys. Their potassium-sparing diuretic effect makes them particularly suitable for
use in conjunction with loop diuretics and thiazides. Both spironolactone and
eplerenone have been shown to reduce mortality in adults with HF when added to
standard therapy [37,38]. This effect is independent of their diuretic effect and is
mediated by inhibition of myocardial fibrosis, an important component of LV
remodeling [39]. A randomized trial in 42 boys with cardiomyopathy secondary to
Duchenne muscular dystrophy demonstrated that the addition of MRA therapy
(eplerenone in this trial) to ACE inhibitor or ARB therapy attenuated the decline in left
ventricular systolic function [40]. Side effects include hyperkalemia (with both drugs)
and gynecomastia (with spironolactone).

Beta blockers — Beta blocker therapy (eg, carvedilol or metoprolol) is usually added
to an established regimen of diuretics and an ACE inhibitor. Beta blockers are used in
children who are stable on other HF medications, have systolic dysfunction with stage
C HF ( table 2), and have a systemic LV (as opposed to certain congenital heart
defects with a systemic right ventricle [RV]). Beta blockers are discontinued in
patients with decompensated HF.

Beta blockers commonly used for management of HF in children include carvedilol

and metoprolol; metoprolol may be preferred for patients with frequent ventricular
ectopy:
● Carvedilol is initiated at a low dose (approximately one-eighth of the eventual
target dose, usually a dose of 0.05 mg/kg per dose given orally twice a day) and
increased every two weeks to minimize side effects. In general, the dose is
doubled after observing the response to the new higher test dose in clinic to a
maximum dose of 0.4 mg/kg given orally twice a day. Side effects that may
preclude dose increase include dizziness, fatigue, hypotension, bradycardia,
bronchospasm, and hypoglycemia.
● Metoprolol is initiated at 0.1 mg/kg per dose orally twice daily and increased
slowly (usually every two weeks) as needed up to 1 mg/kg/day (maximum daily
dose in adults: 2 mg/kg/day or 200 mg/day, whichever is less). Side effects are
similar to those of carvedilol.

Beta blockers counteract the maladaptive effects of chronic sympathetic activation of

the myocardium. In adults with HF, they improve patient survival, reverse LV
remodeling, and decrease myocardial fibrosis. (See "Primary pharmacologic therapy
for heart failure with reduced ejection fraction", section on 'Beta blocker'.)

As is the case with ACE inhibitors, studies of beta blockers in children with HF have
been limited by small sample size, relatively short follow-up, and the use of surrogate
endpoints. A 2009 systematic review of beta blocker therapy in children with HF
concluded there were not enough data to recommend or discourage their use [41].

In a multicenter randomized trial of 161 children with HF and ventricular pump

dysfunction, there were no differences in the number of patients who improved (56
percent in both groups), worsened (24 percent with carvedilol versus 30 percent with
placebo), or were unchanged (19 versus 15 percent) [42]. However, the study was
thought to be underpowered as the clinical course of all children enrolled was better
than expected. There was a trend towards clinical improvement in children with a
systemic LV, but not in those with a systemic RV, suggesting that the response to
carvedilol may be affected by the morphology of the child's systemic ventricle [43].

A subsequent clinical trial in 89 pediatric HF patients also found no difference in

clinical improvement with carvedilol compared with conventional treatment; however,
improvements in echocardiographic parameters and serum BNP levels were noted
with carvedilol [44].

In several small observational studies, beta blocker therapy has been associated with
improved symptoms, improvement in ventricular function, and delay in time to
transplant or death in children with HF [45-49]. Carvedilol therapy has also been
shown to preserve LV function after exposure to anthracyclines at six months follow-
up [50], and to improve LV function when added to ACE inhibitor therapy in patients
with DMD and dilated cardiomyopathy [51]. In a large, retrospective multicenter
review of the Pediatric Health Information System (PHIS) database, a beta blocker was
prescribed upon discharge in 37 percent of pediatric patients admitted with acute
decompensated HF [52].

Digoxin — Digoxin is most commonly used in the treatment of infants and children
with stage C HF who have persistent symptoms despite treatment with other agents
(eg, diuretics and ACE inhibitors). In this setting, digoxin may provide physiologic
benefit and symptom relief. These benefits are generally seen with a low dose (trough
level 0.5 to 0.9 ng/mL). Potential adverse effects (arrhythmias) are rare with this low
level.

Digoxin was previously the mainstay of HF management until the 1990s, but its role
diminished after it was found not to reduce mortality in adults with HF although it
consistently reduced hospitalizations in these studies [53,54]. (See "Secondary
pharmacologic therapy for heart failure with reduced ejection fraction", section on
'Digoxin'.)

Digoxin has a positive inotropic effect (mediated by Na+/K+ ATPase inhibition and
increase in intracellular Ca+), a negative chronotropic effect that slows atrial
conduction, and vagotonic properties that counter symptoms and signs mediated by
the activation of the sympathetic nervous system in HF [55].

Other agents
● Sodium-glucose cotransporter 2 (SGLT2) inhibitors – SGLT2 inhibitors (eg,
dapagliflozin, empagliflozin) are emerging as an important component of HF
therapy in adult patients based upon clinical trial data demonstrating that these
agents improve survival, reduce HF hospitalizations, and improve HF symptoms.
(See "Primary pharmacologic therapy for heart failure with reduced ejection
fraction", section on 'Sodium-glucose co-transporter 2 inhibitors'.)

Data on use of SGLT2 inhibitors in pediatric patients with HF are extremely

limited. None of the available SGLT2 inhibitors are approved by the FDA for this
indication in children.

In a retrospective single-center study of 38 pediatric patients with HF receiving

standard medical therapy, the addition of dapagliflozin was associated with
modest improvements in BNP levels and ventricular EF measurements [56]. The
drug was generally well tolerated; however, six patients (16 percent) experienced
a symptomatic urinary tract infection requiring antibiotic treatment.
● Ivabradine – Ivabradine is not a routine component of pediatric HF
management. However, it is an option for patients with symptomatic stable
chronic HF with reduced ejection fraction who either continue to have a high
resting heart rate despite beta blocker and/or digoxin therapy or who have a
contraindication or intolerance to beta blocker or digoxin use.

Ivabradine is a selective inhibitor of the sinoatrial pacemaker modulating "f-

current" [57]. Ivabradine slows the sinus rate by prolonging the slow
depolarization phase.
 The efficacy of ivabradine in reducing resting heart rate and its safety were
demonstrated in a clinical trial involving 116 children with dilated cardiomyopathy
(DCM) and symptomatic chronic HF receiving stable HF therapy who were
randomly assigned to treatment with ivabradine or placebo [58]. The ivabradine
dose was adjusted to achieve a 20 percent reduction in resting heart rate, which
was achieved in 70 percent of children on ivabradine versus 12 percent of those
on placebo. Among secondary endpoints analyzed at one year, the degree of
improvement in left ventricular ejection fraction from baseline was greater in
ivabradine-treated patients compared with placebo (13.5 versus 6.9 percent).
However, the degree of reduction in N-terminal pro–B-type natriuretic peptide
levels from baseline was similar in both groups. The proportion of patients with
stable or improved New York Heart Association or Ross functional class was also
similar in both groups. Bradycardia occurred more frequently in the ivabradine
group (11 versus 2.4 percent); approximately 5 percent of patients in the
ivabradine group experienced symptomatic bradycardia. Other adverse events
were similar in both groups.

Clinical trials in adult patients have demonstrated that ivabradine reduces HF

hospitalizations, but an effect on mortality has not been demonstrated. For this
reason, its use is limited to patients with chronic HF who do not achieve adequate
heart rate reduction despite standard HF therapy, including maximum tolerated
dose of beta blocker.

Ivabradine is approved by the FDA for treatment of stable symptomatic HF due to

DCM in pediatric patients ≥6 months old [59]. Ivabradine should not be used in
patients with acute decompensated HF, hypotension, sinus node dysfunction,
heart block, pacemaker dependence (heart rate maintained exclusively by
pacemaker), or severe hepatic impairment. In addition, it should be avoided in
patients taking medications that are strong cytochrome CYP34A inhibitors
( table 3) since these would increase ivabradine plasma concentrations.
● Pulmonary vasodilators — Pulmonary vasodilators are used in children with
right HF due to pulmonary hypertension. This is discussed in detail separately.
(See "Pulmonary hypertension in children: Management and prognosis", section
on 'Targeted pulmonary hypertension therapy'.)
 ● Nesiritide – We suggest not routinely using nesiritide for management of
pediatric acute HF. Use of this agent (where available) is generally limited to
carefully selected patients with acute decompensated HF who have not achieved
adequate reduction in filling pressures with other interventions and who have
acceptable hemodynamics (ie, no hypotension or shock). Nesiritide is no longer
available in the United States.

Nesiritide is a recombinant B-type natriuretic peptide that reduces preload and

afterload by promoting diuresis, natriuresis, and arterial and venous dilation,
thereby improving cardiac output without a direct inotropic effect on the
myocardium. In a prospective, open-label study in 63 children with refractory HF,
nesiritide was associated with improved urine output, serum creatinine, and
cardiac function [60,61]. However, trials in adults with acute decompensated HF
have failed to demonstrate improvement in mortality, HF hospitalization rate, or
symptoms with nesiritide use. In addition, there is an associated increased risk of
hypotension. (See "Treatment of acute decompensated heart failure: Specific
therapies", section on 'Approach to vasodilator therapy'.)

Drug therapy for advanced HF — IV diuretics and inotropic agents are generally
used in hospitalized patients with stage D HF ( table 2).

Inotropes — Inotropic agents are used in the setting of low cardiac output (eg,
during acute exacerbations of HF to improve cardiac output and to stabilize patients
awaiting heart transplantation). Their effect is mediated through higher intracellular
cyclic adenylate monophosphate (cAMP) levels, either by increased production
(catecholamines) or by decreased degradation (phosphodiesterase III inhibition).

Catecholamines — Sympathomimetic stimulation by catecholamine agents

improves myocardial contractility and may have an additional beneficial effect on
peripheral vascular beds [62]. Dopamine is the preferred drug during decompensated
HF (usually in combination with intravenous milrinone). Dobutamine has the additive
effect of reducing afterload. Low-dose epinephrine is used in the setting of refractory
hypotension and/or poor end-organ perfusion. (See "Use of vasopressors and
inotropes", section on 'Dopamine' and "Use of vasopressors and inotropes", section
on 'Dobutamine' and "Use of vasopressors and inotropes", section on 'Epinephrine'.)
An arterial catheter and central venous catheter facilitate safe administration, close
monitoring, and careful titration of these medications targeting optimal end-organ
perfusion, as measured by urine output, serum lactate, and mixed venous
saturations.

Milrinone — IV milrinone, a phosphodiesterase III inhibitor, is the preferred drug

for decompensated HF at most institutions. Milrinone increases contractility and
reduces afterload without a significant increase in myocardial oxygen consumption
[63]. A randomized, double-blind, placebo-controlled trial in pediatric postoperative
cardiac surgery patients demonstrated that children treated with high-dose milrinone
infusion (0.75 mcg/kg/min) were at a lower risk for the development of low cardiac
output syndrome (LCOS) compared with children treated with placebo (12 versus 26
percent) [64].

To avoid hypotension, milrinone is initially administered as an IV infusion starting at a

dose of 0.25 mcg/kg/min (without a pre-infusion bolus) and titrated upwards slowly as
needed to a maximum dose of 1 mcg/kg/min.

Milrinone therapy is generally provided in the hospital setting. However, several

centers (including ours) use home milrinone in selected patients awaiting heart
transplantation. In our practice, home milrinone infusion therapy is used in children
who are clinically stable without end-organ dysfunction, with no history of
arrhythmias, who generally are on a milrinone dose ≤0.5 mcg/kg/min and a stable
regimen of oral diuretic therapy, and who are under continuous adult supervision.
Small case series support the safe use of milrinone in this setting [65,66].

NONPHARMACOLOGIC INTERVENTIONS FOR ADVANCED HF

Therapeutic interventions for selected patients with advanced HF refractory to

pharmacologic therapy (stage D) may include:
● Positive pressure ventilation
● Mechanical circulatory support in patients with end-stage HF
● Heart transplantation
Noninvasive ventilation — Noninvasive ventilation (NIV), such as high-flow nasal
cannula (HFNC), continuous positive airway pressure (CPAP), or bilevel positive airway
pressure (BiPAP) ventilation, can be effective in alleviating respiratory distress from
cardiogenic pulmonary edema. NIV promotes alveolar recruitment, improves lung
compliance, and leads to decreased LV preload and afterload [67]. Although there is
high-quality evidence of the benefit of NIV in adult patients with cardiogenic
pulmonary edema, pediatric data are limited [68,69]. (See "Noninvasive ventilation for
acute and impending respiratory failure in children".)

Cardiac resynchronization therapy — Cardiac resynchronization therapy (CRT) may

be an option for some children with stage C and D HF ( table 2) who do not respond
adequately to optimal medical therapy, particularly patients with reduced EF (ie, <35
percent) and a left bundle branch block (LBBB) pattern on electrocardiogram (ECG).

Intraventricular conduction delay or LBBB may worsen HF by causing ventricular

dyssynchrony. CRT uses biventricular pacing to minimize ventricular dyssynchrony. In
adult patients with LV dysfunction, HF, and LBBB, CRT has been shown to improve
hemodynamics and symptoms. (See "Cardiac resynchronization therapy in heart
failure: Indications and choice of system" and "Cardiac resynchronization therapy in
heart failure: Indications and choice of system", section on 'Rationale for CRT'.)

The effectiveness of CRT in the pediatric population is difficult to evaluate because of

the complex anatomic substrates of congenital heart disease (CHD), scar formation
from multiple cardiac surgeries, and a higher proportion of right bundle-branch block
(RBBB) and RV failure than in the adult population [70]. Guidelines used in adult
patients provide a useful reference [71]; however, the typical adult HF scenario of an
LVEF ≤35 percent with LBBB is relatively uncommon in children [72].

There are no randomized controlled trials evaluating CRT in pediatric HF; data on the
outcomes of pediatric CRT are limited to case reports and several retrospective single-
center and multicenter studies with heterogeneous CHD populations [70,73]. In a
multicenter, retrospective analysis of 103 children and young adults with CHD and
prolonged QRS on ECG, CRT was associated with improvement of ventricular EF from
26 to 40 percent [74]. In another single-center retrospective case-control study of 63
patients with symptomatic HF with reduced EF and prolonged QRS on ECG, CRT was
associated with improved heart transplant-free survival [73].

The placement of transvenous, endocardial pacing systems is limited in pediatric

patients due to patient size, and, in CHD patients, due to surgically altered venous
anatomy. Although transvenous leads have been successfully placed in patients who
are <50 kg, doing so may not be in the best long-term interest of the patient because
of the lifelong risk of venous thrombosis, infection, and lead failure necessitating lead
extraction. In patients <50 kg, epicardial lead placement is often necessary which
involves a sternotomy and/or a thoracotomy.

Mechanical circulatory support — In children with decompensated HF with low

cardiac output syndrome unresponsive to medical therapy, mechanical circulatory
support (MCS) can be life-saving. MCS maintains end-organ function and reduces
myocardial oxygen requirements. It is used as a bridge to recovery (extracorporeal
membrane oxygenation [ECMO]) in patients with secondary cardiomyopathy or to
heart transplantation (ECMO or ventricular assist device [VAD]). In a report from the
International Society for Heart and Lung Transplantation (ISHLT), one-third of
pediatric heart transplant recipients received MCS as a bridge to transplantation [75].

The options include the following:

● Extracorporeal membrane oxygenation – ECMO is a total heart-lung bypass
device and is used in the setting of imminent or actual cardiac arrest, such as
postcardiotomy shock following cardiac surgery and acute myocarditis.
Cannulation can be performed percutaneously, and ECMO can provide full
cardiopulmonary support for days to weeks. A multicenter registry review of 3416
neonatal and 4181 pediatric cardiac ECMO cases showed a survival to discharge
rate of 38 and 45 percent, respectively [76]. If myocardial recovery does not occur
or is not expected to occur within two to three weeks, ECMO may be used as a
bridge to a more durable VAD placement and subsequent heart transplantation.
● Ventricular assist device – VAD, a cardiac-only support device, can offer either
univentricular or biventricular support. Multiple devices exist and differ by flow
design (pulsatile, centrifugal, or axial), pump location relative to patient
(implantable, paracorporeal, or extracorporeal), and delivery system
 (percutaneous or central) [77]. They are primarily used in patients awaiting heart
transplantation and have yielded favorable results [78,79]. In a national registry
study of 364 pediatric patients who underwent durable VAD implants between
2012 and 2016, 72 percent were alive at six months and nearly 50 percent had
undergone transplant [80]. Adolescent patients (age 11 to 19 years) had the
highest survival (81 percent survival), whereas survival among infants (age <1
year) was only 47 percent. Serious adverse events were common and included
infection, bleeding, and stroke [80]. VAD options are limited in small children
awaiting heart transplantation due to body size and anatomic considerations,
though new devices are under development [81,82].

The choice of device depends on the etiology of HF, the patient's cardiac anatomy, the
expected length of support, the availability of devices, and the expertise of the
center's clinicians. Serious complications associated with ECMO and VAD include
bleeding (eg, gastrointestinal and intracranial hemorrhage), thromboembolism (eg,
stroke), and infection. (See "Short-term mechanical circulatory assist devices".)

Heart transplantation — Heart transplantation is recommended for end-stage HF

refractory to medical therapy (stage D). It may also be considered for less severe HF
(stage C) associated with severe limitation of activity, significant growth failure,
intractable arrhythmias, or restrictive cardiomyopathy [75,83]. Early referral to a
pediatric transplant center should be considered to optimize medical therapy and the
timing of listing for heart transplant. The decision to pursue heart transplantation is
based upon the expected survival with medical therapy, quality of life, alternative
options for treatment, and estimation of survival post-transplantation. (See 'Outcome'
below and "Heart transplantation in adults: Indications and contraindications".)

MANAGEMENT AND PREVENTION OF HF COMPLICATIONS

Patients with HF are at risk for complications, including thromboembolism,

arrhythmias, and sudden cardiac death.

Thromboembolism — Children with HF due to systemic ventricular dysfunction are at

risk for the formation of intracardiac thrombi, which may result in pulmonary
embolus, cerebral embolic strokes, and, in some cases, death.
The optimal strategy for prevention of thromboembolism in children with HF is
uncertain. There are no controlled trials in children. Many experts (including the
authors of this topic review) use aspirin for prevention of thromboembolism in
children with moderate left ventricular (LV) dysfunction, and warfarin or low molecular
weight heparin (LMWH) for children with severe LV dysfunction, particularly in the
presence of an indwelling catheter and/or a history of prior thrombus. Aspirin can
also be considered in children with restrictive cardiomyopathy if there is marked atrial
dilation. (See "Antithrombotic therapy in patients with heart failure", section on 'Role
of antithrombotic therapy'.)

Children who develop intracardiac thrombi, or other clinically significant

thromboembolic events, are managed with anticoagulation therapy (initially with
unfractionated heparin or LMWH, and subsequently with either LMWH or warfarin).
Management of thrombosis in children is discussed in greater detail separately. (See
"Venous thrombosis and thromboembolism (VTE) in children: Treatment, prevention,
and outcome".)

Arrhythmias — In patients with decreased ventricular function, sustained atrial and

ventricular tachyarrhythmias can rapidly impair hemodynamics. In these patients,
management of the arrhythmia is essential. This may include:
● Cardioversion or defibrillation if necessary (eg, if the patient is acutely unstable).
(See "Management of supraventricular tachycardia (SVT) in children", section on
'Cardioversion' and "Atrial tachyarrhythmias in children", section on 'Acute
management' and "Management and evaluation of wide QRS complex
tachycardia in children", section on 'Unstable patient'.)
● Antiarrhythmic therapy – Antiarrhythmic therapy is warranted if the arrhythmia is
persistent (ie, does not resolve with correction of electrolyte abnormalities or
other possible triggers) and poorly tolerated. Antiarrhythmic medications should
not be used routinely for prevention of arrhythmia in children with HF who have
not previously had arrhythmia.
● Ablation therapy, particularly in the setting of chronic atrial tachyarrhythmias.
(See "Management of supraventricular tachycardia (SVT) in children", section on
 'Catheter ablation' and "Atrial tachyarrhythmias in children", section on 'Focal
atrial tachycardia'.)

The management (both acute and chronic) of specific arrhythmias is discussed in

separate topic reviews:
● Supraventricular tachycardia (including atrioventricular reentrant tachycardia
[AVRT] and atrioventricular nodal reentrant tachycardia [AVNRT]). (See
"Management of supraventricular tachycardia (SVT) in children", section on 'Acute
management'.)
● Focal atrial tachycardia and atrial ectopic tachycardia. (See "Atrial
tachyarrhythmias in children", section on 'Focal atrial tachycardia'.)
● Ventricular tachycardia. (See "Management and evaluation of wide QRS complex
tachycardia in children", section on 'Initial management' and "Management and
evaluation of wide QRS complex tachycardia in children", section on 'Chronic
management'.)

Sudden cardiac death — Implantable cardioverter defibrillator (ICD) placement is

recommended for patients with HF who have survived sudden cardiac arrest (ie,
aborted sudden cardiac death [SCD]). (See "Secondary prevention of sudden cardiac
death in heart failure and cardiomyopathy" and "Sudden cardiac arrest (SCA) and
sudden cardiac death (SCD) in children", section on 'Survivors of SCA'.)

In addition, ICD placement is generally indicated for patients who are at high risk for
SCD due to ventricular arrhythmia, including patients with HF or cardiomyopathy who
have a history of unexplained syncope or recurrent, sustained ventricular
dysrhythmias [71].

The general principles of ICD use and efficacy in children are similar in many respects
to those in adults and application of adult guidelines for ICD implantation is generally
the approach in the older adolescent (ie, ≥16 years). (See "Implantable cardioverter-
defibrillators: Overview of indications, components, and functions", section on
'Indications'.)

There are some unique considerations for ICD placement in pediatric patients,
including the longevity of the device and lead, the size of the patient relative to the
device, and the increased physical activity, particularly in young children. In addition,
many children with ICDs outlive their devices and leads, necessitating complex
extraction and multiple replacement procedures. These issues need to be carefully
considered when evaluating therapeutic options in children with HF. The risks and
benefits of each approach differ by age, size, and overall assessment of risk for SCD.

The risk of sudden death in children with end-stage HF awaiting transplantation is

approximately 1 percent [84]. In contrast to adults, there is little pediatric evidence to
guide decision-making regarding ICD placement for primary prevention of SCD in
children with cardiomyopathy. (See "Primary prevention of sudden cardiac death in
patients with cardiomyopathy and heart failure with reduced LVEF".)

ICD placement in children with hypertrophic cardiomyopathy is discussed in greater

detail separately. (See "Hypertrophic cardiomyopathy in children: Management and
prognosis", section on 'Prevention of sudden cardiac death (ICD placement)'.)

LONG-TERM HEALTH MAINTENANCE

Longitudinal care for children with HF should be closely coordinated with the child's
cardiologist. Important aspects of long-term health care maintenance in children with
HF include:
● Immunizations – Infants and children with HF should receive all routine
childhood vaccinations, including pneumococcal vaccine, yearly influenza vaccine,
COVID-19 vaccine, and respiratory syncytial virus (RSV) immunoprophylaxis for
eligible infants. (See "Standard immunizations for children and adolescents:
Overview" and "Pneumococcal vaccination in children" and "Seasonal influenza in
children: Prevention with vaccines" and "COVID-19: Vaccines", section on
'Children' and "Respiratory syncytial virus infection: Prevention in infants and
children".)
● Monitoring of growth parameters – It is important to monitor growth and
development in children with HF, as it is in all children. Poor weight gain may be
the main clinical sign of HF in young infants and children. (See "Normal growth
patterns in infants and prepubertal children".)
● Monitoring for cardiac symptoms – Between visits with the cardiac specialist,
the primary care provider should monitor for symptoms related to HF (eg, poor
weight gain, tachypnea, dyspnea, syncope). If the patient develops new or
worsening HF symptoms, the patient should be promptly referred to the
specialist for cardiac evaluation. (See "Heart failure in children: Etiology, clinical
manifestations, and diagnosis", section on 'Clinical manifestations'.)
● Treatment of respiratory illnesses – Respiratory illnesses can be associated with
considerable morbidity and mortality in children with HF. It is important to
promptly recognize acute respiratory illnesses and to provide appropriate
treatment if warranted. (See "Community-acquired pneumonia in children:
Outpatient treatment".)
● Exercise and sports participation – Promoting healthy and safe physical activity
in patients with HF is an important part of management. The challenge is to
balance routine daily physical activity and limiting inactivity while minimizing any
potential risks from exercise. Recommendations should be tailored for each
individual based on his or her specific diagnosis and a comprehensive
assessment of the child's exercise capacity. (See 'Exercise and physical activity'
above and "Physical activity and exercise in patients with congenital heart
disease".)
● Antibiotic prophylaxis – Antibiotic prophylaxis for the prevention of bacterial
endocarditis should be provided to cyanotic patients and those with indwelling
central lines. (See "Prevention of endocarditis: Antibiotic prophylaxis and other
measures".)
● Planning of non-cardiac surgery – Children with HF are at increased risk for
adverse events when undergoing surgery and other procedures under
anesthesia. Careful perioperative planning (including consultation with cardiac
anesthesia, coordination with the cardiologist, and appropriate postprocedural
monitoring) are important for pediatric patients with HF undergoing surgery or
other procedures requiring anesthesia/sedation.
● Airplane travel – Airplane travel should be avoided in children with HF who are in
an unstable or decompensated condition. Supplemental oxygen may be
 warranted in select patients during airplane travel. (See "Approach to patients
with heart disease who wish to travel by air or to high altitude".)

OUTCOME

Outcomes for pediatric patients with HF vary considerably depending on the

underlying etiology and severity of HF.
● Outcomes for children with HF – Among patients hospitalized for management
of HF, mortality ranges from 6 to 15 percent [52,85-90]. In a study using data from
the Nationwide Emergency Department Sample database of 5971 pediatric heart
failure-related emergency department visits in 2010, 60 percent required hospital
admission [88]. The median duration of hospitalization was 6 days. Among
admitted patients, the mortality rate was 5.9 percent. Independent risk factors for
mortality included comorbid renal failure and respiratory failure.

For patients with New York Heart Association (NYHA)/Ross class II and III HF
symptoms ( table 4), medical management appears to improve outcomes. In
the Pediatric Carvedilol Study, a prospective clinical trial involving 161 children
with predominantly class II and III HF, medical management included
angiotensin-converting enzyme (ACE) inhibitors in nearly all children, diuretics
and digoxin in approximately 85 percent, beta blocker therapy (carvedilol) in two-
thirds, and spironolactone in approximately one-third [42]. Over the eight-month
study period, 56 percent of patients demonstrated clinical improvement (defined
as improvement in HF class and/or moderate to marked improvement in global
assessment score), 18 percent remained stable, and 26 percent worsened,
including 11 deaths (7 percent) and 18 cardiac transplantations (11 percent).

For children with dilated cardiomyopathy (DCM), outcomes depend on the

etiology, the degree of left ventricular (LV) dysfunction, and the severity of
symptoms [91]. In a registry study of 549 children with DCM who were diagnosed
between 2000 and 2009 and followed for a median of one year, 27 percent
recovered normal LV function and size, 24 percent underwent heart
transplantation, and 9 percent died (median time from diagnosis to death was 3.2
months) [91]. The most frequent diagnoses in this cohort included idiopathic
 DCM (63 percent), myocarditis (17 percent), familial DCM (12 percent), and
neuromuscular disease (eg, Duchenne muscular dystrophy; 5 percent); most
patients (>70 percent) had heart failure symptoms at diagnosis. Independent risk
factors for mortality included presence of heart failure symptoms at diagnosis,
neuromuscular disease, and lower LV shortening fraction; myocarditis was
associated with better survival. Mortality in this cohort was considerably lower
than in an earlier cohort diagnosed with DCM from 1990 to 1999 and followed for
a median of 1.6 years (9 versus 18 percent, respectively), though rates of heart
transplantation were similar (24 percent in both cohorts).
● Outcomes after heart transplantation – Outcomes following pediatric cardiac
transplantation are described in reports from the Registry of the International
Society for Heart and Lung Transplantation (ISHLT), which includes data on
>15,000 pediatric heart transplantations performed at >100 centers around the
world from 1982 to 2018 [92-95]. Overall median survival following heart
transplantation ranges from 13 years for adolescents recipients to 22 years for
infant transplant recipients [75]. Mortality is highest in the first year following
transplant. Survival has improved considerably over time, with estimated five-year
post-transplant survival of 82 percent for patients transplanted in the era from
2009 to 2014 compared with 60 percent for those transplanted in 1982 to 1989
[75].

Risk factors for mortality following heart transplantation include [75]:

• Age of the recipient – The risk of mortality in the first year after transplant is
higher in infants compared with older children. However, among one-year
conditional survivors, infants generally have a better long-term prognosis
compared with adolescents.

• Age of the donor – Older age is associated with higher mortality.

• Longer allograft ischemic time.
• Poor pretransplant renal function.
• Requiring ECMO or ventilator support prior to transplant.
 • Type of cardiac disease – Mortality is higher among children with congenital
heart disease compared with dilated cardiomyopathy.

• Retransplant.
Among survivors of pediatric heart transplantation, functional status at up to
three years post-transplant is generally good, with >80 percent of patients
reporting normal activity or only minor limitations in strenuous activity.
Hospitalizations for the treatment of rejection and/or infection are common,
occurring in 30 to 40 percent of patients in the first three years after
transplantation [75].

SOCIETY GUIDELINE LINKS

Links to society and government-sponsored guidelines from selected countries and

regions around the world are provided separately. (See "Society guideline links: Heart
failure in children".)

SUMMARY AND RECOMMENDATIONS

● Goals of therapy – Therapeutic goals for children with heart failure (HF) are to
relieve symptoms, decrease morbidity (including the risk of hospitalization), slow
the progression of HF, and improve patient survival and quality of life. (See 'Goals
of therapy' above.)
● General measures – General measures that can be applied to all pediatric HF
patients include correcting reversible conditions that may be causing or
contributing to the HF symptoms (eg, anemia, hypertension, renal failure, obesity,
malnutrition, respiratory disorders), ensuring adequate nutrition, and promoting
healthy and safe exercise. (See 'General measures' above.)
● Patients with structural heart disease – For patients with preserved ventricular
function who have HF symptoms due to structural heart defects causing volume
overload (eg, septal defects, patent ductus arteriosus) or pressure overload (eg,
pulmonic stenosis, aortic stenosis, other right or left ventricular outflow tract
 obstruction) ( table 1), the mainstay of management involves surgical or
catheter-based interventions to correct the underlying defects. Medical therapy
may be needed for stabilization or symptom relief while awaiting a more
definitive intervention. (See 'Structural heart disease with preserved ventricular
function' above.)
● Heart failure management – Pharmacologic therapy is generally warranted for
patients with ventricular pump dysfunction and those who require stabilization
before surgical or catheter-based intervention. Because pediatric data are limited,
pharmacologic treatment for children with HF is largely based on evidence from
clinical trials involving adults with HF. (See 'Impaired ventricular function' above
and 'Evidence for efficacy' above.)

HF therapy is provided based on the stage of HF ( table 2). Treatment is not

necessary for stage A (those at risk for HF who have normal cardiac function) (see
'Pharmacologic therapy' above):

• Stage B – For asymptomatic patients with abnormal ventricular function, we

suggest pharmacologic therapy with an angiotensin-converting enzyme (ACE)
inhibitor (Grade 2B). Angiotensin II receptor blockers (ARBs) can be used in
patients who are intolerant of ACE inhibitors. (See 'Renin-angiotensin-
aldosterone system inhibition' above.)

• Stage C – For patients with current or past HF symptoms due to structural or

functional heart disease, we suggest initial treatment with an ACE inhibitor
plus a mineralocorticoid receptor antagonist (Grade 2B). In addition, oral
diuretic therapy is provided as needed to treat fluid overload. After a few weeks
of stability, if there is no improvement in LV dilation and dysfunction, we
suggest adding a beta blocker (Grade 2B). Low-dose digoxin may be added if
needed for symptom relief. (See 'Pharmacologic therapy' above.)

• Stage D – Interventions for patients with end-stage HF who are refractory to

oral medical therapy may include intravenous administration of inotropes and
diuretics and nonpharmacologic interventions such as positive pressure
ventilation, cardiac resynchronization therapy, mechanical circulatory support,
 and heart transplantation. (See 'Drug therapy for advanced HF' above and
'Nonpharmacologic interventions for advanced HF' above.)
● Complications of HF – Management of pediatric patients with HF includes
assessment of risk for complications, including thromboembolism, arrhythmias,
and sudden cardiac death. (See 'Management and prevention of HF
complications' above.)
● Long-term health maintenance – Longitudinal care for children with HF should
be closely coordinated with the child's cardiologist. Important aspects of long-
term health care maintenance in children with HF include routine immunizations,
monitoring of growth parameters, prompt recognition and treatment of
respiratory illnesses, antibiotic prophylaxis if warranted, counseling regarding
exercise, planning of non-cardiac surgery, and advice regarding air travel. (See
'Long-term health maintenance' above.)
● Outcome – Outcomes for pediatric patients with HF vary considerably depending
on the underlying etiology and severity of HF. Among patients hospitalized for
management of HF, mortality is approximately 5 to 15 percent. (See 'Outcome'
above.)
REFERENCES

1. Anand IS, Gupta P. Anemia and Iron Deficiency in Heart Failure: Current Concepts
and Emerging Therapies. Circulation 2018; 138:80.
2. Higgins D, Otero J, Jefferis Kirk C, et al. Iron Laboratory Studies in Pediatric
Patients With Heart Failure from Dilated Cardiomyopathy. Am J Cardiol 2017;
120:2049.
3. Puri K, Price JF, Spinner JA, et al. Iron Deficiency Is Associated with Adverse
Outcomes in Pediatric Heart Failure. J Pediatr 2020; 216:58.
4. Klip IT, Comin-Colet J, Voors AA, et al. Iron deficiency in chronic heart failure: an
international pooled analysis. Am Heart J 2013; 165:575.
5. Zhou X, Xu W, Xu Y, Qian Z. Iron Supplementation Improves Cardiovascular
Outcomes in Patients with Heart Failure. Am J Med 2019; 132:955.
 6. Puri K, Spinner JA, Powers JM, et al. Poor efficacy of oral iron replacement therapy
in pediatric patients with heart failure. Cardiol Young 2022; 32:1302.
7. Azevedo VM, Albanesi Filho FM, Santos MA, et al. [The impact of malnutrition on
idiopathic dilated cardiomyopathy in children]. J Pediatr (Rio J) 2004; 80:211.
8. Castleberry CD, Jefferies JL, Shi L, et al. No Obesity Paradox in Pediatric Patients
With Dilated Cardiomyopathy. JACC Heart Fail 2018; 6:222.
9. Miller TL, Neri D, Extein J, et al. Nutrition in Pediatric Cardiomyopathy. Prog Pediatr
Cardiol 2007; 24:59.
10. Piña IL, Apstein CS, Balady GJ, et al. Exercise and heart failure: A statement from
the American Heart Association Committee on exercise, rehabilitation, and
prevention. Circulation 2003; 107:1210.
11. Rhodes J, Curran TJ, Camil L, et al. Impact of cardiac rehabilitation on the exercise
function of children with serious congenital heart disease. Pediatrics 2005;
116:1339.
12. McBride MG, Binder TJ, Paridon SM. Safety and feasibility of inpatient exercise
training in pediatric heart failure: a preliminary report. J Cardiopulm Rehabil Prev
2007; 27:219.
13. Kirk R, Dipchand AI, Rosenthal DN, et al. The International Society for Heart and
Lung Transplantation Guidelines for the management of pediatric heart failure:
Executive summary. [Corrected]. J Heart Lung Transplant 2014; 33:888.
14. Hsu DT, Pearson GD. Heart failure in children: part II: diagnosis, treatment, and
future directions. Circ Heart Fail 2009; 2:490.
15. Simpson KE, Canter CE. Can adult heart failure regimens be applied to children:
what works and what does not? Curr Opin Cardiol 2012; 27:98.
16. Baylen BG, Johnson G, Tsang R, et al. The occurrence of hyperaldosteronism in
infants with congestive heart failure. Am J Cardiol 1980; 45:305.
17. Ross RD, Daniels SR, Schwartz DC, et al. Plasma norepinephrine levels in infants
and children with congestive heart failure. Am J Cardiol 1987; 59:911.
18. Auerbach SR, Richmond ME, Lamour JM, et al. BNP levels predict outcome in
pediatric heart failure patients: post hoc analysis of the Pediatric Carvedilol Trial.
 Circ Heart Fail 2010; 3:606.
19. Singh TP, Sleeper LA, Lipshultz S, et al. Association of left ventricular dilation at
listing for heart transplant with postlisting and early posttransplant mortality in
children with dilated cardiomyopathy. Circ Heart Fail 2009; 2:591.
20. Engle MA, Lewy JE, Lewy PR, Metcoff J. The use of furosemide in the treatment of
edema in infants and children. Pediatrics 1978; 62:811.
21. Kantor PF, Mertens LL. Clinical practice: heart failure in children. Part II: current
maintenance therapy and new therapeutic approaches. Eur J Pediatr 2010;
169:403.
22. Heo JH, Rascati KL, Lopez KN, Moffett BS. Increased Fracture Risk with Furosemide
Use in Children with Congenital Heart Disease. J Pediatr 2018; 199:92.
23. Mathur K, Hsu DT, Lamour JM, Aydin SI. Safety of Enalapril in Infants: Data from
the Pediatric Heart Network Infant Single Ventricle Trial. J Pediatr 2020; 227:218.
24. Lindle KA, Dinh K, Moffett BS, et al. Angiotensin-converting enzyme inhibitor
nephrotoxicity in neonates with cardiac disease. Pediatr Cardiol 2014; 35:499.
25. Kouatli AA, Garcia JA, Zellers TM, et al. Enalapril does not enhance exercise
capacity in patients after Fontan procedure. Circulation 1997; 96:1507.
26. Hsu DT, Zak V, Mahony L, et al. Enalapril in infants with single ventricle: results of a
multicenter randomized trial. Circulation 2010; 122:333.
27. Duboc D, Meune C, Lerebours G, et al. Effect of perindopril on the onset and
progression of left ventricular dysfunction in Duchenne muscular dystrophy. J Am
Coll Cardiol 2005; 45:855.
28. Duboc D, Meune C, Pierre B, et al. Perindopril preventive treatment on mortality in
Duchenne muscular dystrophy: 10 years' follow-up. Am Heart J 2007; 154:596.
29. Bengur AR, Beekman RH, Rocchini AP, et al. Acute hemodynamic effects of
captopril in children with a congestive or restrictive cardiomyopathy. Circulation
1991; 83:523.
30. Lewis AB, Chabot M. The effect of treatment with angiotensin-converting enzyme
inhibitors on survival of pediatric patients with dilated cardiomyopathy. Pediatr
Cardiol 1993; 14:9.
31. Mori Y, Nakazawa M, Tomimatsu H, Momma K. Long-term effect of angiotensin-
converting enzyme inhibitor in volume overloaded heart during growth: a
controlled pilot study. J Am Coll Cardiol 2000; 36:270.
32. Gisler F, Knirsch W, Harpes P, Bauersfeld U. Effectiveness of angiotensin-
converting enzyme inhibitors in pediatric patients with mid to severe aortic valve
regurgitation. Pediatr Cardiol 2008; 29:906.
33. Lipshultz SE, Lipsitz SR, Sallan SE, et al. Long-term enalapril therapy for left
ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin
Oncol 2002; 20:4517.
34. Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of
LCZ696 Followed by a 52-week Study of LCZ696 Compared With Enalapril in Pediat
ric Patients With Heart Failure. Study record detail. Available at: https://clinicaltrial
s.gov/ct2/show/NCT02678312 (Accessed on October 02, 2020).
35. Shaddy R, Canter C, Halnon N, et al. Design for the sacubitril/valsartan (LCZ696)
compared with enalapril study of pediatric patients with heart failure due to
systemic left ventricle systolic dysfunction (PANORAMA-HF study). Am Heart J
2017; 193:23.
36. ENTRESTO® (sacubitril and valsartan) tablets, for oral use. US Food and Drug Adm
inistration. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/20
19/207620s013lbl.pdf (Accessed on December 20, 2019).
37. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and
mortality in patients with severe heart failure. Randomized Aldactone Evaluation
Study Investigators. N Engl J Med 1999; 341:709.
38. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in
patients with left ventricular dysfunction after myocardial infarction. N Engl J Med
2003; 348:1309.
39. Tsutamoto T, Wada A, Maeda K, et al. Effect of spironolactone on plasma brain
natriuretic peptide and left ventricular remodeling in patients with congestive
heart failure. J Am Coll Cardiol 2001; 37:1228.
40. Raman SV, Hor KN, Mazur W, et al. Eplerenone for early cardiomyopathy in
Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled
trial. Lancet Neurol 2015; 14:153.
41. Frobel AK, Hulpke-Wette M, Schmidt KG, Läer S. Beta-blockers for congestive heart
failure in children. Cochrane Database Syst Rev 2009; :CD007037.
42. Shaddy RE, Boucek MM, Hsu DT, et al. Carvedilol for children and adolescents with
heart failure: a randomized controlled trial. JAMA 2007; 298:1171.
43. O'Connor MJ, Rosenthal DN, Shaddy RE. Outpatient management of pediatric
heart failure. Heart Fail Clin 2010; 6:515.
44. Huang M, Zhang X, Chen S, et al. The effect of carvedilol treatment on chronic
heart failure in pediatric patients with dilated cardiomyopathy: a prospective,
randomized-controlled study. Pediatr Cardiol 2013; 34:680.
45. Shaddy RE, Tani LY, Gidding SS, et al. Beta-blocker treatment of dilated
cardiomyopathy with congestive heart failure in children: a multi-institutional
experience. J Heart Lung Transplant 1999; 18:269.
46. Bruns LA, Chrisant MK, Lamour JM, et al. Carvedilol as therapy in pediatric heart
failure: an initial multicenter experience. J Pediatr 2001; 138:505.
47. Azeka E, Franchini Ramires JA, Valler C, Alcides Bocchi E. Delisting of infants and
children from the heart transplantation waiting list after carvedilol treatment. J Am
Coll Cardiol 2002; 40:2034.
48. Rusconi P, Gómez-Marín O, Rossique-González M, et al. Carvedilol in children with
cardiomyopathy: 3-year experience at a single institution. J Heart Lung Transplant
2004; 23:832.
49. Blume ED, Canter CE, Spicer R, et al. Prospective single-arm protocol of carvedilol
in children with ventricular dysfunction. Pediatr Cardiol 2006; 27:336.
50. Kalay N, Basar E, Ozdogru I, et al. Protective effects of carvedilol against
anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2006; 48:2258.
51. Kajimoto H, Ishigaki K, Okumura K, et al. Beta-blocker therapy for cardiac
dysfunction in patients with muscular dystrophy. Circ J 2006; 70:991.
52. Moffett BS, Price JF. National prescribing trends for heart failure medications in
children. Congenit Heart Dis 2015; 10:78.
53. Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin from patients
with chronic heart failure treated with angiotensin-converting-enzyme inhibitors.
RADIANCE Study. N Engl J Med 1993; 329:1.
54. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in
patients with heart failure. N Engl J Med 1997; 336:525.
55. Shaddy RE. Optimizing treatment for chronic congestive heart failure in children.
Crit Care Med 2001; 29:S237.
56. Newland DM, Law YM, Albers EL, et al. Early Clinical Experience with Dapagliflozin
in Children with Heart Failure. Pediatr Cardiol 2023; 44:146.
57. Dobre D, Borer JS, Fox K, et al. Heart rate: a prognostic factor and therapeutic
target in chronic heart failure. The distinct roles of drugs with heart rate-lowering
properties. Eur J Heart Fail 2014; 16:76.
58. Bonnet D, Berger F, Jokinen E, et al. Ivabradine in Children With Dilated
Cardiomyopathy and Symptomatic Chronic Heart Failure. J Am Coll Cardiol 2017;
70:1262.
59. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/206143s007lbl.pdf (A
ccessed on May 14, 2019).
60. Mahle WT, Cuadrado AR, Kirshbom PM, et al. Nesiritide in infants and children
with congestive heart failure. Pediatr Crit Care Med 2005; 6:543.
61. Jefferies JL, Price JF, Denfield SW, et al. Safety and efficacy of nesiritide in pediatric
heart failure. J Card Fail 2007; 13:541.
62. Schweigmann U, Meierhofer C. Strategies for the treatment of acute heart failure
in children. Minerva Cardioangiol 2008; 56:321.
63. Wessel DL. Managing low cardiac output syndrome after congenital heart surgery.
Crit Care Med 2001; 29:S220.
64. Hoffman TM, Wernovsky G, Atz AM, et al. Efficacy and safety of milrinone in
preventing low cardiac output syndrome in infants and children after corrective
surgery for congenital heart disease. Circulation 2003; 107:996.
65. Berg AM, Snell L, Mahle WT. Home inotropic therapy in children. J Heart Lung
Transplant 2007; 26:453.
66. Apostolopoulou SC, Vagenakis GA, Tsoutsinos A, et al. Ambulatory Intravenous
Inotropic Support and or Levosimendan in Pediatric and Congenital Heart Failure:
Safety, Survival, Improvement, or Transplantation. Pediatr Cardiol 2018; 39:1315.
67. Tkacova R, Rankin F, Fitzgerald FS, et al. Effects of continuous positive airway
pressure on obstructive sleep apnea and left ventricular afterload in patients with
heart failure. Circulation 1998; 98:2269.
68. Kovacikova L, Skrak P, Dobos D, Zahorec M. Noninvasive positive pressure
ventilation in critically ill children with cardiac disease. Pediatr Cardiol 2014;
35:676.
69. Testa G, Iodice F, Ricci Z, et al. Comparative evaluation of high-flow nasal cannula
and conventional oxygen therapy in paediatric cardiac surgical patients: a
randomized controlled trial. Interact Cardiovasc Thorac Surg 2014; 19:456.
70. Motonaga KS, Dubin AM. Cardiac resynchronization therapy for pediatric patients
with heart failure and congenital heart disease: a reappraisal of results. Circulation
2014; 129:1879.
71. Epstein AE, DiMarco JP, Ellenbogen KA, et al. 2012 ACCF/AHA/HRS focused update
incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of
cardiac rhythm abnormalities: a report of the American College of Cardiology
Foundation/American Heart Association Task Force on Practice Guidelines and the
Heart Rhythm Society. Circulation 2013; 127:e283.
72. Schiller O, Dham N, Greene EA, et al. Pediatric Dilated Cardiomyopathy Patients
Do Not Meet Traditional Cardiac Resynchronization Criteria. J Cardiovasc
Electrophysiol 2015; 26:885.
73. Chubb H, Rosenthal DN, Almond CS, et al. Impact of Cardiac Resynchronization
Therapy on Heart Transplant-Free Survival in Pediatric and Congenital Heart
Disease Patients. Circ Arrhythm Electrophysiol 2020; 13:e007925.
74. Dubin AM, Janousek J, Rhee E, et al. Resynchronization therapy in pediatric and
congenital heart disease patients: an international multicenter study. J Am Coll
 Cardiol 2005; 46:2277.
75. Rossano JW, Cherikh WS, Chambers DC, et al. The Registry of the International
Society for Heart and Lung Transplantation: Twentieth Pediatric Heart
Transplantation Report-2017; Focus Theme: Allograft ischemic time. J Heart Lung
Transplant 2017; 36:1060.
76. Haines NM, Rycus PT, Zwischenberger JB, et al. Extracorporeal Life Support
Registry Report 2008: neonatal and pediatric cardiac cases. ASAIO J 2009; 55:111.
77. Adachi I, Fraser CD Jr. Mechanical circulatory support for infants and small
children. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 2011; 14:38.
78. Adachi I, Khan MS, Guzmán-Pruneda FA, et al. Evolution and impact of ventricular
assist device program on children awaiting heart transplantation. Ann Thorac Surg
2015; 99:635.
79. Blume ED, Naftel DC, Bastardi HJ, et al. Outcomes of children bridged to heart
transplantation with ventricular assist devices: a multi-institutional study.
Circulation 2006; 113:2313.
80. Blume ED, VanderPluym C, Lorts A, et al. Second annual Pediatric Interagency
Registry for Mechanical Circulatory Support (Pedimacs) report: Pre-implant
characteristics and outcomes. J Heart Lung Transplant 2018; 37:38.
81. Lorts A, Zafar F, Adachi I, Morales DL. Mechanical assist devices in neonates and
infants. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 2014; 17:91.
82. Adachi I. Current status and future perspectives of the PumpKIN trial. Transl
Pediatr 2018; 7:162.
83. Canter CE, Shaddy RE, Bernstein D, et al. Indications for heart transplantation in
pediatric heart disease: a scientific statement from the American Heart
Association Council on Cardiovascular Disease in the Young; the Councils on
Clinical Cardiology, Cardiovascular Nursing, and Cardiovascular Surgery and
Anesthesia; and the Quality of Care and Outcomes Research Interdisciplinary
Working Group. Circulation 2007; 115:658.
84. Rhee EK, Canter CE, Basile S, et al. Sudden death prior to pediatric heart
transplantation: would implantable defibrillators improve outcome? J Heart Lung
 Transplant 2007; 26:447.
85. Rossano JW, Kim JJ, Decker JA, et al. Prevalence, morbidity, and mortality of heart
failure-related hospitalizations in children in the United States: a population-based
study. J Card Fail 2012; 18:459.
86. Shamszad P, Hall M, Rossano JW, et al. Characteristics and outcomes of heart
failure-related intensive care unit admissions in children with cardiomyopathy. J
Card Fail 2013; 19:672.
87. Price JF, Kantor PF, Shaddy RE, et al. Incidence, Severity, and Association With
Adverse Outcome of Hyponatremia in Children Hospitalized With Heart Failure.
Am J Cardiol 2016; 118:1006.
88. Mejia EJ, O'Connor MJ, Lin KY, et al. Characteristics and Outcomes of Pediatric
Heart Failure-Related Emergency Department Visits in the United States: A
Population-Based Study. J Pediatr 2018; 193:114.
89. Amdani S, Marino BS, Rossano J, et al. Burden of Pediatric Heart Failure in the
United States. J Am Coll Cardiol 2022; 79:1917.
90. Lasa JJ, Gaies M, Bush L, et al. Epidemiology and Outcomes of Acute
Decompensated Heart Failure in Children. Circ Heart Fail 2020; 13:e006101.
91. Singh RK, Canter CE, Shi L, et al. Survival Without Cardiac Transplantation Among
Children With Dilated Cardiomyopathy. J Am Coll Cardiol 2017; 70:2663.
92. Rossano JW, Singh TP, Cherikh WS, et al. The International Thoracic Organ
Transplant Registry of the International Society for Heart and Lung
Transplantation: Twenty-second pediatric heart transplantation report - 2019;
Focus theme: Donor and recipient size match. J Heart Lung Transplant 2019;
38:1028.
93. Singh TP, Hsich E, Cherikh WS, et al. The International Thoracic Organ Transplant
Registry of the International Society for Heart and Lung Transplantation: 23rd
pediatric heart transplantation report-2020; focus on deceased donor
characteristics. J Heart Lung Transplant 2020; 39:1028.
94. Singh TP, Cherikh WS, Hsich E, et al. The International Thoracic Organ Transplant
Registry of the International Society for Heart and Lung Transplantation: Twenty-
 fourth pediatric heart transplantation report - 2021; focus on recipient
characteristics. J Heart Lung Transplant 2021; 40:1050.
95. Singh TP, Cherikh WS, Hsich E, et al. The International thoracic organ transplant
registry of the international society for heart and lung transplantation: Twenty-
fifth pediatric heart transplantation report-2022; focus on infant heart
transplantation. J Heart Lung Transplant 2022; 41:1357.

Topic 14520 Version 29.0

© 2024 UpToDate, Inc. All rights reserved.